Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-03-08

FDA Approved: JUXTAPID — Supplemental Application (Amryt Pharmaceuticals DAC)

View source ↗

Summary

FDA approved Amryt Pharmaceuticals DAC's supplemental application for JUXTAPID (lomitapide mesylate).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JUXTAPID (lomitapide)

Snippet

SUPPL AP for JUXTAPID (LOMITAPIDE MESYLATE)